Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07516496

Metabolic Phenotyping in vEDS

Metabolic Phenotyping in Individuals With Vascular Ehlers-Danlos Syndrome (vEDS)

Status
Recruiting
Phase
Study type
Observational
Enrollment
15 (estimated)
Sponsor
Cambridge University Hospitals NHS Foundation Trust · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Accepted

Summary

This research study will investigate whether people with vascular Ehlers-Danlos syndrome (vEDS), a rare inherited condition, have problems with the way their body stores and uses fat (adipose tissue). vEDS is caused by changes in a gene called COL3A1, which makes a protein important for the structure of many tissues. While vEDS is best known for making blood vessels fragile, there is some early evidence that it may also affect fat tissue and increase the risk of problems such as insulin resistance (where the body does not respond properly to insulin) and diabetes. Fat tissue is important for keeping the body healthy. It stores extra energy, but it also sends signals to other organs. If fat tissue cannot expand or work properly, fat can build up in the liver or muscles instead, leading to high blood sugar, high cholesterol, and greater risk of diabetes and heart disease. In this study, we will invite 12-17 adults with genetically confirmed vEDS to take part, along with a group of age-, sex-, and weight-matched controls without vEDS. Participants will attend a research visit at Addenbrooke's Hospital, Cambridge. They will have measurements of body fat distribution (using a DEXA scan), a liver scan, blood tests, and a standard oral glucose tolerance test (drinking a sugary drink with blood samples before and after). Some participants may also choose to provide a small fat biopsy under local anaesthetic to allow more detailed analysis of tissue structure. The main aim is to see whether people with vEDS show changes in fat distribution and insulin sensitivity compared to those without vEDS.

Conditions

Interventions

TypeNameDescription
OTHERNo intervention, observationalThere is no intervention

Timeline

Start date
2026-03-05
Primary completion
2030-03-04
Completion
2031-04-04
First posted
2026-04-08
Last updated
2026-04-08

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT07516496. Inclusion in this directory is not an endorsement.